Background

Transcatheter aortic valve implantation (TAVI) has been recognized as a primary strategy in treatment of severe aortic stenosis (AS) in high-risk patients. Recently along with the progress of technology some data was obtained to elucidate safety and good clinical efficacy of TAVI in patients of intermediate surgical risk.

Aim

The objective was to evaluate the mid-term results of applying TAVI in treatment of AS.

Aim

The objective was to evaluate the mid-term results of applying TAVI in treatment of AS.

Material and methods

110 patients with a median age of 77 ± 6,4 (60-91) years were included. All patients had severe aortic stenosis with peak pressure gradient 87±6.6mmHg. Mean EuroSCORE was 8,9%. We have used both Edwards Sapien/Sapiens XT (ES) and Medtronic CoreValve bioprostheses (CV), the decision being made with regards to different aortic valve and vascular anatomy. In 79 cases implantation was performed through transfemoral access and in 22 cases – transapical access was used due to vascular abnormalities. In the rest 9 cases we used direct transaortic (6 patients) and transsubclavian approach (3 patients). General anesthesia was performed in 88%.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. OP-001 An Under-estimated Complication ff Atrial Fibrillation Ablation: Gastroparesis
2. OP-038 Reduction of Eosinophil Percentage may Predict the Mortality from Acute Coronary Syndromes
3. OP-065 Increased Platelet-to-Lymphocyte Ratio is Related to Slow Coronary Flow
4. OP-100 Pulmonary Function after Transcatheter Aortic Valve Implantation in Patients with High Risk Aortic Stenosis

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree